TABLE 5.
Detailed serologic results from 11 patients with a possible recent infection in the prospective study
| Study ID | Cutoff for positive EBV IgM samples obtained on each platforma |
Immunoblot IgM status | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Liaison |
Immulite |
BioPlex |
||||||||
| VCA IgM | VCA IgG | EBNA IgG | VCA IgM | VCA IgG | EBNA IgG | VCA IgM | VCA IgG | EBNA IgG | ||
| 1116 | >160 (+) | <10 (-) | <3 (-) | 11.9 (+) | 1.3 (+) | 0.4 (-) | >4.0 (+) | 0.2 (-) | 0.2 (-) | ND |
| 1187 | >160 (+) | >750 (+) | <3 (-) | 7.2 (+) | ND | 4.2 (+) | 4.0 (+) | 0.6 (-) | 0.2 (-) | ND |
| 1215 | >160 (+) | 66 (+) | <3 (-) | 7.7 (+) | ND | 1.2 (+) | >4.0 (+) | 0.2 (-) | 0.2 (-) | ND |
| 1225 | 53 (+) | 135 (+) | 6 (-) | 0.2 (-) | ND | 28.0 (+) | 0.7 (-) | ND | 8.0 (+) | Negative |
| 1244 | 56 (+) | <10 (-) | <3 (-) | 0.4 (-) | 0.2 (-) | 0.4 (-) | 2.1 (+) | 0.2 (-) | 0.2 (-) | Negative |
| 1262 | 71 (+) | NDb | 29 (+) | 3.7 (+) | 26.0 (+) | 0.7 (-) | 1.8 (+) | ND | 1.5 (+) | ND |
| 1297 | 105 (+) | 56 (+) | <3 (-) | 0.4 (-) | 7.3 (+) | 0.5 (-) | 0.4 (-) | ND | 1.5 (+) | Inconclusive |
| 1309 | 62 (+) | 99 (+) | 3 (-) | 0.7 (-) | 12.9 (+) | 0.2 (-) | 2.5 (+) | 0.4 (-) | 0.2 (-) | Positive |
| 1397 | 80 (+) | 530 (+) | <3 (-) | 1.9 (+) | ND | 25.9 (+) | 4.0 (+) | ND | 4.9 (+) | ND |
| 1408 | 40 (+) | 51 (+) | <3 (-) | 1.1 (+) | 11.3 (+) | 0.3 (-) | 0.5 (-) | 2.0 (+) | 0.2 (-) | Positive |
| 1470 | 34 (-) | 130 (+) | <3 (-) | 0.4 (-) | 18.2 (+) | 1.0 (-) | 1.3 (+) | 4.7 (+) | 0.5 (-) | Negative |
a
Values are expressed as mU/liter for Liaison and as ratios for BioPlex and Immulite. The applied cutoffs for the assays on Liaison were 40 mU/liter for VCA IgM, 20 mU/liter for VCA IgG, and 20 mU/liter for EBNA IgG. For the assays performed on BioPlex and Immulite, a cutoff 1.1 (ratio) was used. The result interpretation as positive or negative is indicated in parentheses.
b
ND, not determined.